SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

BACKGROUND: Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab. METHODS: This multicenter, randomize...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Rochlitz, Christoph, Bigler, Martin, von Moos, Roger, Bernhard, Jürg, Matter-Walstra, Klazien, Wicki, Andreas, Zaman, Khalil, Anchisi, Sandro, Küng, Marc, Na, Kyung-Jae, Bärtschi, Daniela, Borner, Markus, Rordorf, Tamara, Rauch, Daniel, Müller, Andreas, Ruhstaller, Thomas, Vetter, Marcus, Trojan, Andreas, Hasler-Strub, Ursula, Cathomas, Richard, Winterhalder, Ralph
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5057418/
https://ncbi.nlm.nih.gov/pubmed/27724870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2823-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares